JP5823512B2 - ３−フェノキシメチルピロリジン化合物の結晶性形態 - Google Patents

３−フェノキシメチルピロリジン化合物の結晶性形態 Download PDF

Info

Publication number
JP5823512B2
JP5823512B2 JP2013518688A JP2013518688A JP5823512B2 JP 5823512 B2 JP5823512 B2 JP 5823512B2 JP 2013518688 A JP2013518688 A JP 2013518688A JP 2013518688 A JP2013518688 A JP 2013518688A JP 5823512 B2 JP5823512 B2 JP 5823512B2
Authority
JP
Japan
Prior art keywords
crystalline
composition
pain
disorder
crystalline salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013518688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532170A (ja
JP2013532170A5 (enExample
Inventor
ダイスケ ローランド サイトウ，
ダイスケ ローランド サイトウ，
ミロスラフ ラプタ，
ミロスラフ ラプタ，
Original Assignee
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44510052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5823512(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー, セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー filed Critical セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Publication of JP2013532170A publication Critical patent/JP2013532170A/ja
Publication of JP2013532170A5 publication Critical patent/JP2013532170A5/ja
Application granted granted Critical
Publication of JP5823512B2 publication Critical patent/JP5823512B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013518688A 2010-07-09 2011-06-30 ３−フェノキシメチルピロリジン化合物の結晶性形態 Expired - Fee Related JP5823512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36277310P 2010-07-09 2010-07-09
US61/362,773 2010-07-09
PCT/US2011/042518 WO2012006205A1 (en) 2010-07-09 2011-06-30 Crystalline form of a 3-phenoxymethylpyrrolidine compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015063809A Division JP2015120752A (ja) 2010-07-09 2015-03-26 ３−フェノキシメチルピロリジン化合物の結晶性形態

Publications (3)

Publication Number Publication Date
JP2013532170A JP2013532170A (ja) 2013-08-15
JP2013532170A5 JP2013532170A5 (enExample) 2014-06-19
JP5823512B2 true JP5823512B2 (ja) 2015-11-25

Family

ID=44510052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013518688A Expired - Fee Related JP5823512B2 (ja) 2010-07-09 2011-06-30 ３−フェノキシメチルピロリジン化合物の結晶性形態
JP2015063809A Withdrawn JP2015120752A (ja) 2010-07-09 2015-03-26 ３−フェノキシメチルピロリジン化合物の結晶性形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015063809A Withdrawn JP2015120752A (ja) 2010-07-09 2015-03-26 ３−フェノキシメチルピロリジン化合物の結晶性形態

Country Status (20)

Country Link
US (4) US8163794B2 (enExample)
EP (1) EP2590941A1 (enExample)
JP (2) JP5823512B2 (enExample)
KR (1) KR20130041916A (enExample)
CN (1) CN103038211B (enExample)
AR (1) AR083512A1 (enExample)
AU (1) AU2011276416B2 (enExample)
BR (1) BR112013000602A2 (enExample)
CA (1) CA2803090A1 (enExample)
CL (1) CL2013000085A1 (enExample)
CO (1) CO6680604A2 (enExample)
IL (1) IL223584A0 (enExample)
MX (1) MX2013000334A (enExample)
NZ (1) NZ605490A (enExample)
PH (1) PH12013500051A1 (enExample)
RU (1) RU2013105479A (enExample)
SG (1) SG186789A1 (enExample)
TW (1) TW201206882A (enExample)
WO (1) WO2012006205A1 (enExample)
ZA (1) ZA201300154B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
CN103038211B (zh) * 2010-07-09 2015-04-15 施万生物制药研发Ip有限责任公司 3-苯氧基甲基吡咯烷化合物的结晶形式
US12369722B2 (en) 2018-05-23 2025-07-29 L&P Property Management Company Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate
US11013340B2 (en) 2018-05-23 2021-05-25 L&P Property Management Company Pocketed spring assembly having dimensionally stabilizing substrate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
EP1184372B1 (en) * 2000-08-31 2006-04-26 Pfizer Limited Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs)
WO2005092835A1 (en) * 2004-03-05 2005-10-06 Eli Lilly And Company Pharmaceutical compounds
CN101506164A (zh) * 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
CA2687721A1 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
ES2434250T3 (es) * 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
EP2419405A1 (en) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
CN103038211B (zh) * 2010-07-09 2015-04-15 施万生物制药研发Ip有限责任公司 3-苯氧基甲基吡咯烷化合物的结晶形式

Also Published As

Publication number Publication date
AU2011276416A1 (en) 2013-02-14
US9120746B2 (en) 2015-09-01
EP2590941A1 (en) 2013-05-15
KR20130041916A (ko) 2013-04-25
IL223584A0 (en) 2013-03-05
US8791151B2 (en) 2014-07-29
TW201206882A (en) 2012-02-16
US20150080450A1 (en) 2015-03-19
CA2803090A1 (en) 2012-01-12
AU2011276416B2 (en) 2015-04-02
CN103038211A (zh) 2013-04-10
NZ605490A (en) 2014-10-31
MX2013000334A (es) 2013-02-26
US8163794B2 (en) 2012-04-24
US20120010265A1 (en) 2012-01-12
AR083512A1 (es) 2013-03-06
CN103038211B (zh) 2015-04-15
CO6680604A2 (es) 2013-05-31
US8383669B2 (en) 2013-02-26
ZA201300154B (en) 2013-09-25
WO2012006205A1 (en) 2012-01-12
SG186789A1 (en) 2013-02-28
JP2013532170A (ja) 2013-08-15
PH12013500051A1 (en) 2017-10-25
JP2015120752A (ja) 2015-07-02
RU2013105479A (ru) 2014-08-20
US20120178790A1 (en) 2012-07-12
US20140018407A1 (en) 2014-01-16
CL2013000085A1 (es) 2013-03-15
BR112013000602A2 (pt) 2016-07-05

Similar Documents

Publication Publication Date Title
US11596624B2 (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
JP5405571B2 (ja) ３−（フェノキシフェニルメチル）ピロリジン化合物
JP2014218519A (ja) ３−フェノキシメチルピロリジン化合物
JP2015120752A (ja) ３−フェノキシメチルピロリジン化合物の結晶性形態
EP2550252B1 (en) 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
JP5705239B2 (ja) セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140421

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140725

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151007

R150 Certificate of patent or registration of utility model

Ref document number: 5823512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees